Zacks Investment Research upgraded shares of Heron Therapeutics Inc. (NASDAQ:HRTX) from a sell rating to a hold rating in a research report released on Tuesday.
According to Zacks, “Heron Therapeutics Inc. is a specialty pharmaceutical company. The company is developing products using its proprietary Biochronomer (TM) polymer-based drug delivery platform. Its product portfolio includes APF530, is being developed for the prevention of acute chemotherapy-induced nausea and vomiting. Heron Therapeutics Inc., formerly known as A.P. Pharma, Inc., is based in REDWOOD CITY CA. “
A number of other equities research analysts also recently weighed in on HRTX. Cowen and Company reaffirmed a buy rating on shares of Heron Therapeutics in a research note on Saturday, July 9th. Leerink Swann reaffirmed a buy rating and set a $33.00 price target on shares of Heron Therapeutics in a research note on Sunday, October 2nd. JMP Securities reaffirmed a buy rating on shares of Heron Therapeutics in a research note on Friday, September 9th. Brean Capital assumed coverage on Heron Therapeutics in a research note on Tuesday, October 4th. They set a buy rating and a $41.00 price target for the company. Finally, Jefferies Group cut their price target on Heron Therapeutics from $46.00 to $40.00 and set a buy rating for the company in a research note on Monday, October 3rd. One analyst has rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Heron Therapeutics presently has an average rating of Buy and an average target price of $42.29.
Shares of Heron Therapeutics (NASDAQ:HRTX) opened at 15.42 on Tuesday. Heron Therapeutics has a 12-month low of $15.13 and a 12-month high of $31.32. The firm’s 50-day moving average is $18.11 and its 200-day moving average is $18.86.
Heron Therapeutics (NASDAQ:HRTX) last announced its quarterly earnings data on Monday, August 8th. The biotechnology company reported ($1.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.96) by $0.21. Equities research analysts anticipate that Heron Therapeutics will post ($4.39) earnings per share for the current fiscal year.
In other Heron Therapeutics news, insider Robert Rosen sold 100,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 10th. The stock was sold at an average price of $23.30, for a total value of $2,330,000.00. Following the sale, the insider now owns 102,640 shares of the company’s stock, valued at approximately $2,391,512. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 20.31% of the stock is owned by corporate insiders.
Several hedge funds have recently made changes to their positions in the company. BlackRock Group LTD raised its stake in shares of Heron Therapeutics by 9.0% in the second quarter. BlackRock Group LTD now owns 10,816 shares of the biotechnology company’s stock valued at $195,000 after buying an additional 897 shares during the last quarter. State Board of Administration of Florida Retirement System raised its stake in shares of Heron Therapeutics by 8.3% in the second quarter. State Board of Administration of Florida Retirement System now owns 16,739 shares of the biotechnology company’s stock valued at $302,000 after buying an additional 1,283 shares in the last quarter. American International Group Inc. raised its stake in shares of Heron Therapeutics by 8.1% in the second quarter. American International Group Inc. now owns 18,293 shares of the biotechnology company’s stock valued at $330,000 after buying an additional 1,369 shares in the last quarter. Swiss National Bank raised its stake in shares of Heron Therapeutics by 3.0% in the second quarter. Swiss National Bank now owns 51,900 shares of the biotechnology company’s stock valued at $937,000 after buying an additional 1,500 shares in the last quarter. Finally, BlackRock Advisors LLC raised its stake in shares of Heron Therapeutics by 13.3% in the second quarter. BlackRock Advisors LLC now owns 15,104 shares of the biotechnology company’s stock valued at $273,000 after buying an additional 1,769 shares in the last quarter.
About Heron Therapeutics
Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.